Member Info for Taff8

If you don't take opportunites like this one, you shouldn't be in the market.. In@3.6 target 10p

Yes there is another o e in English

Go ahead for pdsb covid19 vaccine huge news

Just bought back in, won't be boring for long pdsb leak rns should land later, Brazil covid19 vaccine funded.

When you see a profitable company with £85m cash and £20m mkt cap, you buy and hold will reach 15p within 2mths easy.

Very little stock in free float here, don't be surprised to see 10p very soon,redicilous undervalued must have £85m+ cash, update due for July.

Revenue for June £12m this going back to 15p eady

Cash £72m

Hsbc were buying about a month ago

https://www.wkyt.com/2020/08/13/promising-results-from-covid-19-vaccine-candidate-tested-at-uk/

Insiders took all the placing shares and with $21m already in the bank puzzled why cash call was needed there, expect huge news imminent from many front, 2x covid19 vaccines, cancer jv with Merck at phase, $35m cash and mkt cap $60m.

If you've done some research you'll notice it joint trial with Merck and done in state side

MD Anderson Cancer Center, Houston, USA, in collaboration with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. MRx0518-I-003 is in combination with preoperative radiotherapy in resectable pancreatic cancer.

Expect 70 by lunchtime, should be busy afternoon with the yanks taking interest.

Looks like the traders are out and ii joining for the real re rate here,can only go one way, multiple shots on goal over next few months, one goal and it 5bags.

quickly, if it's found to work.

Duncan Peyton, CEO of 4D pharma, said being able to develop safe treatments was the 'holy grail' for treatments.

He said: 'Being able to safely treat the hyper-inflammation in the lungs, related to COVID-19, should be priority when developing therapies for patients suffering from the more serious respiratory effects of the infection.

'Given the excellent safety profile of our drug, we would eventually like to treat patients with mild symptoms, before they need to go to hospital - reducing the chances of respiratory complications and the requirement of intensive care.'

Duncan Peyton, Chief Executive Officer, commented "Over the past year we made impressive progress in all aspects of our business, towards the delivery of a new class of drug, Live Biotherapeutics. We now look forward to the year having set up multiple near-to-mid-term catalysts as we generate robust clinical data with multiple shots on goal. "

Can't believe this is so cheap, just like sng@35 and tiz@47p was.

Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma commented, "Reducing hyperinflammation, particularly in the lungs, is key to preventing the exacerbation of symptoms associated with more severe COVID-19. 4D pharma has shown MRx-4DP0004 has the ability to target inflammation in the lungs, potentially reducing the respiratory issues central to COVID-19. 4D pharma aims to use this study to generate robust, meaningful clinical data that will support a safe immunomodulatory Live Biotherapeutic intervention for patients hospitalised with COVID-19."



He added, "Immunomodulatory intervention in COVID-19 is supported by recent positive results from the UK's RECOVERY trial, showing dexamethasone reduces the risk of death in hospitalised patients. We believe MRx-4DP0004 has a mechanism of action that may be complementary to that of dexamethasone, which has now become standard-of-care across the UK's National Health Service (NHS). Importantly, in our ongoing asthma study the addition of MRx-4DP0004 to glucocorticoid treatments (the same class of medicines as dexamethasone) has to date been safe and well tolerated, positioning MRx-4DP0004 to be able to progress rapidly in this new standard-of-care setting. 4D pharma intends to develop MRx-4DP0004 to prevent hospitalised COVID-19 patients deteriorating to the point of needing invasive ventilation and intensive care, and thus alleviate the greatest burdens facing healthcare services. Following positive data from the COVID-19 clinical trial, 4D pharma intends to explore the potential utility of MRx-4DP0004 in additional viral infections like influenza."





About MRx-4DP0004

MRx-4DP0004 is a single-strain Live Biotherapeutic in development for the treatment of asthma and COVID-19. It has demonstrated strong and significant efficacy in industry standard preclinical models of steroid-resistant severe asthma. MRx-4DP0004 was shown to reduce both neutrophils and eosinophils in prophylactic and therapeutic settings in vivo. The efficacy was also reflected in a reduction in histopathological lung inflammation, and specific subsets of T cells, dendritic cells and inflammatory cytokines.



4D is currently investigating MRx-4DP0004 in a Phase I/II study in patients with partly-controlled asthma. The study, taking place at sites across the UK, is evaluating the safety and preliminary clinical efficacy of MRx-4DP0004 in addition to standard maintenance therapy such as inhaled corticosteroids (ICS) and long acting beta agonists (LABA), in up to 90 patients. For more information about the clinical study please visit https://clinicaltrials.gov/ct2/show/NCT03851250.



The Company has received expedited acceptance from the MHRA to conduct a Phase II study of MRx-4DP0004 in up to 90 patients hospitalised with suspected or confirmed COVID-19. For more information about the clinical study please visit https://clinicaltrials.gov/ct2/show/NCT04363372.





About 4D



Founded in F

About the BHT-II-0002 study

This study has recruited over 300 patients in 35 investigator sites in the USA and the UK. The interim analysis included evaluation of the primary endpoint of the study, which is based on the number of overall responders in each group.The definition of an overall responder is IBS subtype specific and consists of two components. For both IBS subtypes, the first component is the weekly average of abdominal pain intensity. Improvement is defined as a decrease of at least 30% compared with baseline. The second component is different for the two IBS subtypes and relates to stool frequency per week for IBS-C and a reduction in incidence of loose stool consistency for IBS-D compared with baseline. In order for a subject to be classed as a responder, both components must show improvement in the same week for at least 50% of the treatment period of 8 weeks.



About 4D

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.



4D's Live Biotherapeutic Products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.?The Company has five clinical studies in progress, namely a Phase II clinical study of BLAUTIX® in Irritable Bowel Syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer and a Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.



For more information, refer to https://www.4dpharmaplc.com.





Contact Information:



4D

Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130

Investor Relations ir@4dpharmaplc.com



N+1 Singer - Nominated Adviser and Joint Broker +44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)



Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker



Image Box PR

Neil Hunter / Michelle Boxall

Tel +44 (0)20 8943 4685

neil@ibcomms.agency / michelle@ibcomms.agency





This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Auth

4D has more potential and looking for 5bags easy from here, no brainer